AGILENT TECHNOLOGIES, INC. A

Agilent's Ignite operating system, launched at the start of FY25, has significantly improved execution and fostered a new mindset. It enhanced top-line growth through an enterprise pricing program, more than doubling price growth compared to FY24. Ignite also led to faster decision-making, meaningful procurement cost savings through global vendor contracts, and enabled a rapid, coordinated response to global tariff changes, resulting in over $150 million in annualized savings. This system has also strengthened organizational readiness for M&A integration, exemplified by the successful BIOVECTRA integration.

Customer-focused innovation was a key driver of success, with products like the next-generation Infinity III delivering up to 30% productivity improvement and driving double-digit LC growth in H2 FY25. The Pro iQ LC/MS saw an 'amazing ramp,' contributing to over 50% LCMS growth in Q4. The recently introduced Altura bio-inert LC column also experienced rapid adoption, with orders an order of magnitude greater than past column launches, indicating strong demand for increased sensitivity in applications like oligos and GLP-1s.

Agilent's unified sales and service model is a cornerstone of its success, fostering deep customer relationships. Insights from the service team now account for 30% of all sales leads, which convert at more than double the rate of other sales funnel channels. The company is further enhancing customer intimacy by deploying AI within its CRM for predictive insights and personalized content, and using virtual agents to complement on-site support in select markets.

The Pharma market grew 12% in Q4, benefiting from reduced uncertainty around MFN tariff deals and strong product offerings. Biotech spending increased in the low 20s (low double digits excluding CDMO), with recovery starting in well-funded large caps. While still early, improving funding and accelerating M&A activity bode well for small and mid-sized biotech customers in FY26, though it's too soon to call a full inflection point.

GLP-1 related revenue reached $40 million in Q4, split 60% from the BIOVECTRA CDMO business and 40% from analytical tools, contributing to a total of $130 million for FY25. Pharma reshoring represents a significant opportunity, with an estimated $1 billion addressable market for Agilent by 2030, and initial orders expected to materialize by the end of FY26. The company is actively engaged in conversations with pharma companies regarding R&D and tech investments for reshoring initiatives.

China revenue declined 4% in Q4, falling short of low single-digit growth expectations, with declines in food and environmental offsetting growth in biopharma and CAM. The company expects China to be flat in FY26, taking a prudent approach by excluding substantial stimulus benefits from guidance. The Academia and Government end market declined 10% in Q4 due to U.S. federal spending reductions, with continued softness expected in FY26, particularly in the Americas.

Agilent expects to fully mitigate current tariffs in FY26 through a combination of cost savings and pricing actions. However, FY26 EPS guidance includes a 3 percentage point headwind from a 2.5% increase in the tax rate to 14.5%. This increase is attributed to new global minimum tax regulations, including Pillar 2 and OB3, and other jurisdictional changes, which have now solidified in the company's tax provision.